Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Compounding pharmacies use active pharmaceutical ingredients – the part of the medication that produces therapeutic effects – ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Recent research suggests that behavioral and environmental strategies could extend meal duration and reduce the amount of ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.